S1PR1 and myeloid sarcoma: Thus, fingolimod (sphingosine-1-phosphate receptor, S1PR), like endogenous S1P, may lead to a slight, transient reduction in blood pressure after initiation of fingolimod therapy in relapsing MS patients, followed by a small increase in both systolic and diastolic blood pressure.